MARKET

KALA

KALA

Kala Pharmaceuticals Inc
NASDAQ
0.4771
-0.0262
-5.21%
Opening 09:37 09/30 EDT
OPEN
0.5252
PREV CLOSE
0.5033
HIGH
0.5300
LOW
0.4603
VOLUME
20.39M
TURNOVER
--
52 WEEK HIGH
123.00
52 WEEK LOW
0.4010
MARKET CAP
9.23M
P/E (TTM)
-0.0066
1D
5D
1M
3M
1Y
5Y
1D
KALA Bio Signs LOI To Acquire Nationwide Telehealth Platform; Shares Rise
NASDAQ · 4h ago
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 4h ago
KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why
Benzinga · 8h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 1d ago
KALA Bio Inks Letter Of Intent To Acquire U.S.-Based Management Services Firm For ~$15M
Benzinga · 1d ago
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Newsfile · 1d ago
Weekly Report: what happened at KALA last week (0921-0925)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 5d ago
More
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Webull offers KALA BIO Inc stock information, including NASDAQ: KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.